(Información remitida por la empresa firmante)
Last, I want to highlight that Hansa Biopharma AB was recently certified as a Great Place to Work® for the fourth consecutive year. This certification reflects our successful efforts over the past years to not only build and maintain a high-performance team, but also to create a rewarding and stimulating workplace for our employees, enabling us to continue to attract and retain the very best people in the industry. I look forward to keeping you updated on our continued progress, with several upcoming important milestones to be achieved across our platform and franchises in the coming period, as we continue our efforts to develop new, transformative medicines for patients suffering from serious, rare immunologic diseases.”
Upcoming milestones and news flow
Q4 2023 GBS Phase 2: First data readout
Q4 2023 AMR Phase 2: Full data readout
Q4 2023 Sarepta DMD pre-treatment Phase 1b: Commence clinical study
2024 GBS Phase 2: Outcome of the comparative efficacy analysis to IGOS data
2024 Genethon Crigler-Najjar Phase 1/2: Initiate clinical study with imlifidase prior to GNT-0003
2024 HNSA-5487 (Lead NiceR candidate): Further analysis around endpoints to be completed in 2024 incl. lead indication
2024 U.S. ConfIdeS (Kidney tx) Phase 3: Complete randomization
2025 U.S. ConfIdeS (Kidney tx) Phase 3: BLA submission
Updated financial calendar 2023/2024
Feb 2, 2024 Full-year Report for January – December 2023
Mar 20, 2024 Annual Report 2023
Apr 17, 2024 Interim Report for January – March 2024
July 17, 2024 Half-year Report January – June 2024
Oct 23, 2024 Interim Report for January – September 2024
Conference call details
Hansa Biopharma will host a telephone conference today Thursday, October 26, 2023, 14:00 CET / 8:00am EST.
The event will be hosted by Hansa Biopharma’s CEO, Søren Tulstrup, CCO and U.S. President, Matthew Shaulis and CFO, Donato Spota. The presentation will be held in English.
Slides used in the presentation will be live on the company website during the call under “Events & Presentations” and will also be made available online after the call.
To participate in the telephone conference, please use the dial-in details provided below:
Sweden: +46 31 311 51 03
United Kingdom: +44 203 769 6819
United States: +1 646 787 0157
Participant access code: 765135
The webcast will be available on https://hansabiopharma.eventcdn.net/events/q3-2023-conference-call
The interim report and latest investor presentation can be downloaded from our web:
Interim report January to September 2023https://www.hansabiopharma.com/investors/financial-reports/
Investor road show presentation Q3, 2023 https://www.hansabiopharma.com/investors/presentations/
This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act.
CONTACT:
For further information, please contact:
Klaus Sindahl, VP Head of Investor Relations
M: +46 (0) 709–298 269
E: klaus.sindahl@hansabiopharma.com
Stephanie Kenney, VP Global Corporate Affairs
M: +1 (484) 319 2802
E: stephanie.kenney@hansabiopharma.com
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/hansa-biopharma-interim-report-january-september-2023-301968390.html